Literature DB >> 23220632

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.

Mickael Decressac1, Banafsheh Kadkhodaei, Bengt Mattsson, Ariadna Laguna, Thomas Perlmann, Anders Björklund.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) and its close relative neurturin are currently in clinical trials for neuroprotection in patients with Parkinson disease (PD). However, in animal models of PD, GDNF fails to protect nigral dopamine (DA) neurons against α-synuclein-induced neurodegeneration. Using viral vector delivery of human wild-type α-synuclein to nigral DA neurons in rats, we show that the intracellular response to GDNF is blocked in DA neurons that overexpress α-synuclein. This block is accompanied by reduced expression of the transcription factor Nurr1 and its downstream target, the GDNF receptor Ret. We found that Ret expression was also reduced in nigral DA neurons in PD patients. Conditional knockout of Nurr1 in mice resulted in reduced Ret expression and blockade of the response to GDNF, whereas overexpression of Nurr1 restored signaling, providing protection of nigral DA neurons against α-synuclein toxicity. These results suggest that Nurr1 is a regulator of neurotrophic factor signaling and a key player in the cellular defense against α-synuclein toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220632     DOI: 10.1126/scitranslmed.3004676

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  109 in total

1.  Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5XFAD mice, an animal model of Alzheimer's disease.

Authors:  Minho Moon; Inhye Jeong; Chun-Hyung Kim; Jihong Kim; Paula K J Lee; Inhee Mook-Jung; Pierre Leblanc; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2014-09-16       Impact factor: 5.372

2.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

Review 3.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.

Authors:  Mickael Decressac; Nikolaos Volakakis; Anders Björklund; Thomas Perlmann
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 5.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

6.  Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.

Authors:  Xiaomin Su; D Luke Fischer; Xin Li; Krystof Bankiewicz; Caryl E Sortwell; Howard J Federoff
Journal:  Mol Ther       Date:  2017-05-15       Impact factor: 11.454

7.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

8.  A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro.

Authors:  Sean L Hammond; Stephen Safe; Ronald B Tjalkens
Journal:  Neurosci Lett       Date:  2015-09-14       Impact factor: 3.046

9.  Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.

Authors:  Xiaobo Wei; Huimin Gao; Jing Zou; Xu Liu; Dan Chen; Jinchi Liao; Yunqi Xu; Long Ma; Beisha Tang; Zhuohua Zhang; Xiang Cai; Kunling Jin; Ying Xia; Qing Wang
Journal:  Mol Neurobiol       Date:  2015-10-26       Impact factor: 5.590

Review 10.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.